NYAX vs. URGN
NYAX (Nayax Ltd) and URGN (UroGen Pharma Ltd.) are both stocks. NYAX operates in Information Technology Services (Technology), while URGN operates in Biotechnology (Healthcare). Over the past 3 years, NYAX returned 47.06%/yr vs 45.07%/yr for URGN. At a 0.07 correlation, their price movements are largely independent.
Performance
NYAX vs. URGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NYAX achieves a 25.71% return, which is significantly lower than URGN's 49.40% return.
NYAX
- 1D
- -2.54%
- 1M
- -6.43%
- YTD
- 25.71%
- 6M
- 33.63%
- 1Y
- 34.31%
- 3Y*
- 47.06%
- 5Y*
- —
- 10Y*
- —
URGN
- 1D
- 4.23%
- 1M
- 21.11%
- YTD
- 49.40%
- 6M
- 48.39%
- 1Y
- 138.84%
- 3Y*
- 45.07%
- 5Y*
- 15.86%
- 10Y*
- —
NYAX vs. URGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
NYAX Nayax Ltd | 25.71% | 73.53% | 53.08% | -3.30% | -42.48% |
URGN UroGen Pharma Ltd. | 49.40% | 119.91% | -29.00% | 69.11% | 3.99% |
Correlation
The correlation between NYAX and URGN is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.01 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.08 |
Correlation (All Time) Calculated using the full available price history since Sep 21, 2022 | 0.07 |
Fundamentals
NYAX:
$2.64B
URGN:
$1.76B
NYAX:
$0.77
URGN:
-$2.73
NYAX:
5.76
URGN:
12.15
NYAX:
$429.22M
URGN:
$140.49M
NYAX:
$195.18M
URGN:
$126.24M
NYAX:
$69.76M
URGN:
-$117.04M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NYAX vs. URGN — Risk / Return Rank
NYAX
URGN
NYAX vs. URGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Nayax Ltd (NYAX) and UroGen Pharma Ltd. (URGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NYAX | URGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.23 | ||
| Sortino ratioReturn per unit of downside risk | -1.30 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.32 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 1.48 | 3.31 | -1.83 |
| Martin ratioReturn relative to average drawdown | 3.31 | 6.87 | -3.56 |
Loading charts...
Drawdowns
NYAX vs. URGN - Drawdown Comparison
The maximum NYAX drawdown since its inception was -52.18%, smaller than the maximum URGN drawdown of -93.98%. Use the drawdown chart below to compare losses from any high point for NYAX and URGN.
Loading charts...
Drawdown Indicators
| NYAX | URGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -52.18% | -93.98% | +41.80% |
Max Drawdown (1Y)Largest decline over 1 year | -23.26% | -42.22% | +18.96% |
Max Drawdown (3Y)Largest decline over 3 years | -31.25% | -82.64% | +51.39% |
Max Drawdown (5Y)Largest decline over 5 years | — | -82.64% | — |
Current DrawdownCurrent decline from peak | -16.09% | -46.44% | +30.35% |
Average DrawdownAverage peak-to-trough decline | -23.64% | -61.48% | +37.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.41% | 20.32% | -9.91% |
Volatility
NYAX vs. URGN - Volatility Comparison
Nayax Ltd (NYAX) has a higher volatility of 14.11% compared to UroGen Pharma Ltd. (URGN) at 12.68%. This indicates that NYAX's price experiences larger fluctuations and is considered to be riskier than URGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NYAX | URGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.11% | 12.68% | +1.43% |
Volatility (6M)Calculated over the trailing 6-month period | 30.37% | 44.04% | -13.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.75% | 67.38% | -26.63% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 51.40% | 91.62% | -40.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 51.40% | 79.43% | -28.03% |
Dividends
NYAX vs. URGN - Dividend Comparison
Neither NYAX nor URGN has paid dividends to shareholders.
Financials
NYAX vs. URGN - Financials Comparison
This section allows you to compare key financial metrics between Nayax Ltd and UroGen Pharma Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NYAX vs. URGN - Profitability Comparison
NYAX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Nayax Ltd reported a gross profit of 48.02M and revenue of 105.91M. Therefore, the gross margin over that period was 45.3%.
URGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, UroGen Pharma Ltd. reported a gross profit of 46.82M and revenue of 50.96M. Therefore, the gross margin over that period was 91.9%.
NYAX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Nayax Ltd reported an operating income of 4.10M and revenue of 105.91M, resulting in an operating margin of 3.9%.
URGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, UroGen Pharma Ltd. reported an operating income of -20.26M and revenue of 50.96M, resulting in an operating margin of -39.8%.
NYAX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Nayax Ltd reported a net income of 1.27M and revenue of 105.91M, resulting in a net margin of 1.2%.
URGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, UroGen Pharma Ltd. reported a net income of -23.57M and revenue of 50.96M, resulting in a net margin of -46.3%.
Frequently Asked Questions
NYAX and URGN have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NYAX has higher volatility (14.11%) compared to URGN (12.68%). In terms of maximum drawdown, NYAX dropped -52.18% vs URGN's -93.98%.
URGN currently has the higher Sharpe Ratio (2.08 vs 0.85), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NYAX and URGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer